Chemical Nameibalizumab-uiyk
Dosage FormInjectable (intravenous; 150 mg/mL)
Drug ClassMonoclonal antibodies
CompanyTaimed Biologics USA
Approval Year2018


  • Trogarzo in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
Last updated on 1/13/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Trogarzo (ibalizumab-uiyk) Prescribing Information2020Theratechnologies Inc., Montréal, Québec Canada
Document TitleYearSource
Phase 3 study of ibalizumab for multidrug-resistant HIV-12018The New England Journal of Medicine